Bérangère S. Joly - Concepedia

Author

Bérangère S. Joly

Also Known As

B JOLY, B Joly, B S Joly, B. JOLY, B. Joly, B.S. Joly, Berangere Joly, Berangere S. Joly, Berangère S. Joly, Bérangère Joly

122

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Hôpital Lariboisière Université Paris Cité Assistance Publique – Hôpitaux de Paris Sorbonne Université Hôpital Saint-Antoine

About

Bérangère S. Joly is an author at Hôpital Lariboisière specializing in medicine, hematology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	660
2	Public Health	3	3	95
3	Health Sciences	2	2	25
4	Allergy	2	2	24
5	Natural Sciences	1	1	34

Bérangère S. Joly

Publications

Citations

H-Index

Page 1

	Year	Citations
Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19 Bérangère S. Joly, Virginie Siguret, Agnès Veyradier Intensive Care Medicine ThrombosisCritical Care MedicineIll PatientsCovid-19 PandemicHematology	2020	208
An open conformation of ADAMTS‐13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura Elien Roose, An‐Sofie Schelpe, Bérangère S. Joly, Journal of Thrombosis and Haemostasis ThrombosisBlood PlateletHematologyMolecular BiologyPathology	2017	88
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy Bérangère S. Joly, Alain Stépanian, Thierry Leblanc, The Lancet Haematology ThrombopoiesisThrombosisFrench National RegistryPediatric HematologyImmunodeficiencies	2016	78
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura Elien Roose, An‐Sofie Schelpe, Edwige Tellier, Blood	2020	74
ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw–Schulman Syndrome Bérangère S. Joly, Pierre Boisseau, Elien Roose, Thrombosis and Haemostasis	2018	65
Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies Bérangère S. Joly, Virginie Barbay, Jeanne‐Yvonne Borg, Thrombosis Research ThrombosisInfertilityFertilityThrombin Generation TestCoagulation Activation	2013	60
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak* L. Frumholtz, Jean‐David Bouaziz, Maxime Battistella, British Journal of Dermatology	2021	54
Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID‐19 patients Bérangère S. Joly, Michaël Darmon, Charlotte Dekimpe, Journal of Thrombosis and Haemostasis InflammationThrombosisVon Willebrand FactorCardiovascular DiseaseStrong Inflammation	2021	44
Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement Bérangère S. Joly, Alain Stépanian, David Hajage, Thrombosis Research BiochemistryNatural SciencesMedicineBioanalysisPeptide Library	2014	34
Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis Sandrine Valade, Bérangère S. Joly, Agnès Veyradier, PLoS ONE	2021	34

Page 1